https://www.thebodypro.com/category/hiv-treatments-in-development/tag/id-week

The Latest

Promo Image

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

Antibodies

Ibalizumab Effective Against Drug-Resistant HIV in 48-Week Data

The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial Img

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial

A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017 Img

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

Jacob Lalezari, M.D., and Daniel Kuritzkes, M.D.

Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab

HIV clinicians who have patients in declining health due to extensive HIV drug resistance may soon have a new lifesaving option. Ibalizumab, an HIV entry inhibitor in development, shows highly encouraging antiretroviral activity in the days after it ...

What's Hot in HIV Cure Research? Img

What's Hot in HIV Cure Research?

When it comes to an HIV cure, what do we know now and what are the main areas of focus for future research? Irini Sereti, M.D., reviewed and analyzed the current strategies in cure research, during a presentation at IDWeek 2016 in New Orleans.

Promo Image

What's Hot in HIV Cure Research?

When it comes to an HIV cure, what do we know now and what are the main areas of focus for future research? Irini Sereti, M.D., reviewed and analyzed the current strategies in cure research, during a presentation at IDWeek 2016 in New Orleans.

What Helps and What Hinders Participation in HIV Clinical Trials? Img

What Helps and What Hinders Participation in HIV Clinical Trials?

In this interview, Prema Menezes, Ph.D., discusses what motivates people living with HIV to enter into clinical trials and what stops those who have never participated from volunteering.

Promo Image

What 2014 Development Has the Biggest Impact on HIV Care?

Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …

Promo Image

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.